323 related articles for article (PubMed ID: 27207748)
21. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Hadoux J; Schlumberger M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
[TBL] [Abstract][Full Text] [Related]
23. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
24. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
25. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
26. Higher
Mulè C; Ciampi R; Ramone T; Prete A; Matrone A; Cappagli V; Torregrossa L; Basolo F; Elisei R; Romei C
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680178
[TBL] [Abstract][Full Text] [Related]
27. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
[TBL] [Abstract][Full Text] [Related]
28. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
29. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
30. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
Bruce JY; Bible KC; Chintakuntlawar AV
Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
[No Abstract] [Full Text] [Related]
31. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
[No Abstract] [Full Text] [Related]
32. Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?
Marchand L; Nozières C; Walter T; Descotes F; Decaussin-Petrucci M; Joly MO; Lapras V; Bournaud C; Borson-Chazot F
Acta Oncol; 2016 Aug; 55(8):1064-6. PubMed ID: 27173015
[No Abstract] [Full Text] [Related]
33. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
35. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
[TBL] [Abstract][Full Text] [Related]
36. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
37. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
[TBL] [Abstract][Full Text] [Related]
39. Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.
Oczko-Wojciechowska M; Swierniak M; Krajewska J; Kowalska M; Kowal M; Stokowy T; Wojtas B; Rusinek D; Pawlaczek A; Czarniecka A; Szpak-Ulczok S; Gawlik T; Chmielik E; Tyszkiewicz T; Nikiel B; Lange D; Jarzab M; Wiench M; Jarzab B
Sci Rep; 2017 Feb; 7():42074. PubMed ID: 28181547
[TBL] [Abstract][Full Text] [Related]
40. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
